MedTrace Logo

Observation vs Progesterone Treatment for Management of Uterine Arteriovenous Malformation

NCT05491343 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-08-08

No results posted yet for this study

Summary

A randomized trial which compares conservative management to progesterone based treatment for arteriovenous malformation

Conditions

  • Arteriovenous Malformations

Interventions

DRUG

MedroxyPROGESTERone Injection [Depo-Provera]

The drug-induced endometrial changes would likely to prevent the shedding of endometrium, in turn preventing the exposure of AVM.

DEVICE

Other

Follow up using US

Sponsors & Collaborators

  • HaEmek Medical Center, Israel

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-31
Primary Completion
2022-12-31
Completion
2024-01-31
FDA Drug
Yes
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05491343 on ClinicalTrials.gov